Sodium Polystyrene Sulfonate for Hyperkalemia

Abstract

Background: The management of hyperkalemia, particularly in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), has garnered significant attention in recent years, especially regarding the use of sodium polystyrene sulfonate (SPS).  Literature Review: The systematic review conducted by (Wing Sherwin Wong et al., 2020) underscores the lack of high-quality evidence supporting the widespread application of SPS, despite its historical use. The review's findings illustrate significant variability in study designs and dosing regimens, which complicate the determination of its efficacy. Further contributing to this discourse, (Ren et al., 2012) investigate prescription patterns of SPS and calcium polystyrene sulfonate (CPS) among CKD patients on renin–angiotensin–aldosterone system inhibitors (RAASi). The comparative analysis by (Atiquzzaman et al., 2012) highlights the limitations of existing randomized controlled trials (RCTs) and suggests that CPS may offer clinical advantages over SPS, prompting further investigation into the relative safety and efficacy of these resins. Finally, the contemporary overview provided by (Tian et al., 2013) details the mechanism of action of SPS and introduces RDX7675, a re-engineered alternative that shows promise in terms of potassium-binding capacity and tolerability. This development could signify a shift in therapeutic strategies for managing hyperkalemia, aligning with the need for safer and more effective treatment options in CKD patients.  Conclusion: In conclusion, the literature reveals a complex landscape regarding the use of SPS for hyperkalemia management in CKD and ESRD patients. While SPS remains a commonly used treatment, significant concerns regarding its efficacy and safety profile persist. The need for individualized treatment strategies, ongoing research, and the exploration of alternative therapies like CPS and RDX7675 is evident to ensure optimal patient outcomes in this vulnerable population.